Masahiro Kami, the executive director of Japan's Medical Governance Research Institute, and an outside director of SBI Pharma Co., Ltd. and SBI Biotech Co., Ltd., complained that the new coronavirus measures should be reviewed from the beginning. Kami said, "The low number of infected people in Japan is due to the limited number of PCR tests.